吉西他滨与卡介苗膀胱内灌注治疗初治低级别中危非肌层浸润性膀胱癌的比较
回顾性分析151例初治低级别中危非肌层浸润性膀胱癌患者,78例接受卡介苗、73例接受吉西他滨诱导灌注。中位随访卡介苗组54个月、吉西他滨组36个月,校正混杂因素后吉西他滨复发风险高于卡介苗(P = .02),进展风险两组相似(P = .87);不良事件卡介苗组62%、吉西他滨组38%(P = .02)。
要点
- 初治低级别中危非肌层浸润性膀胱癌中,吉西他滨复发风险高于卡介苗(P = .02)。
- 吉西他滨与卡介苗在预防疾病进展方面疗效相当(P = .87)。
- 不良事件发生率卡介苗组62% vs 吉西他滨组38%(P = .02)。
核心结论
- 在初治中危非肌层浸润性膀胱癌患者中,吉西他滨与卡介苗相比与更高的复发风险相关(P = .02),但两种治疗在预防疾病进展方面疗效相当(P = .87)。
研究设计与样本
- 回顾性分析纳入151例按国际膀胱癌工作组标准分类的低级别中危非肌层浸润性膀胱癌患者,均无诱导膀胱内治疗史,其中78例接受卡介苗、73例接受吉西他滨诱导灌注。
主要发现
- 两组完成6周诱导治疗的比例均为100%,卡介苗组47%、吉西他滨组53%接受维持治疗(P = .46)。
- 卡介苗组维持治疗中位剂次为6(IQR:3-9),吉西他滨组为8(IQR:4-10)(P = .83)。
- 卡介苗组中位随访54个月,吉西他滨组中位随访36个月。
- 校正年龄、国际膀胱癌工作组亚组、治疗年份、术后单次灌注及维持治疗后,吉西他滨与卡介苗相比复发风险更高(P = .02),进展风险两组相似(P = .87)。
- 不良事件发生率卡介苗组62% vs 吉西他滨组38%(P = .02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with intermediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) are recommended to receive induction intravesical chemotherapy or immunotherapy. However, the comparison between gemcitabine and bacillus Calmette-Guérin (BCG) in treatment-naïve patients with low-grade IR-NMIBC remains underexplored. The aim of this study was to evaluate the efficacy of gemcitabine compared with BCG in a cohort of treatment-naïve patients with IR-NMIBC. MATERIALS AND METHODS: A retrospective analysis was conducted on patients with low-grade IR-NMIBC, classified according to International Bladder Cancer Group criteria, with no history of induction intravesical treatment. Patients received either induction intravesical BCG or gemcitabine. Recurrence was defined as histologically confirmed cancer during follow-up, while progression included stage/grade progression. Kaplan-Meier estimates were used for survival analysis, and multivariable Cox analysis identified factors associated with recurrence and progression. RESULTS: Of the 151 patients with IR-NMIBC, 78 received BCG and 73 received gemcitabine. Both groups completed the 6-week induction treatment at similar rates (100%), and maintenance therapy was administered to 47% of BCG-treated patients and 53% of gemcitabine-treated patients (P = .46). The median number of maintenance doses was 6 (IQR: 3-9) in the BCG group and 8 (IQR: 4-10) in the gemcitabine group (P = .83). Median follow-up was 54 months for patients receiving BCG and 36 months for patients receiving gemcitabine. After adjusting for age, International Bladder Cancer Group subgroups, year of treatment, single postoperative instillation, and maintenance therapy, gemcitabine was associated with a higher risk of recurrence compared with BCG (P = .02), while the risk of progression remained similar between the 2 groups (P = .87). Adverse events were observed in 62% of patients treated with BCG and 38% of patients treated with gemcitabine (P = .02). CONCLUSIONS: Gemcitabine is associated with a higher risk of recurrence than BCG in treatment-naïve patients with IR-NMIBC. However, both treatments show comparable efficacy in preventing disease progression.
引用
- Khene ZE, Bhanvadia R, Attia S, et al. Gemcitabine vs Bacillus Calmette-Guérin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer. J Urol. 2025. PMID: 39929084. doi:10.1097/JU.0000000000004472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。